肝胆肿瘤分子诊断临床应用专家共识

Consensus for clinical application of molecular diagnosis on hepatobiliary carcinoma

为规范肝胆系统原发恶性肿瘤相关分子标志物在临床诊断、疗效评估及预后预测等方面的应用,本共识分别从外周血及组织学水平,针对近年来研究结果较为明确的肝胆肿瘤相关蛋白质、基因表达层面的分子标志物,在诊断、治疗、分子分型方面的研究进展及临床应用指导意义等做了详尽的总结,提出了专家指导意见。同时对肝胆肿瘤相关血清学、组织病理学、二代测序等实验室检测的标准、结果判读、报告内容及全过程质量管理等也提出了规范化的建议;旨在为一线临床工作人员普及肝胆肿瘤分子诊疗最新知识的基础上,提供科学、合理选择个体化精准诊疗方案的可执行依据。

In hepatobiliary carcinoma,serologic and histologic biomarkers including proteins and genes have been recommended and categorized for cancer diagnosis,targeted therapy and immunotherapy regimen selection,as well as prognostic prediction at different levels.To standardize the application of molecular biomarkers in clinical diagnosis,therapeutic evaluation,and prognosis prediction of primary hepatobiliary carcinoma,the specialist committee has summarized the current well studies biomarkers with clinical significance in both serum and tumor tissue as well as provided professional agreements on their potential utilization in this consensus.Moreover,we have made recommendations on standards for laboratory detection,technical operation,data analysis,result interpretation,clinical report,and the whole-process quality management in serological,histopathological detection and next-generation sequencing.According to these,the committee aims to offer clinical staffs with scientific and practical references and guidance to achieve better personalized treatment decisions from these up-to-date knowledges of molecular diagnosis on hepatobiliary carcinoma.